The British pharmaceutical company AstraZeneca has announced an investment of 15 billion dollars by 2030 in China.[1][2] The money will be used to expand drug production, research and development.[1][2] This is the company's largest investment in this country to date.[1] The announcement was made during the visit of British Prime Minister Keir Starmer to Beijing.[1] China is the company's second largest market after the US, and it has been operating there for more than 30 years.[1] The investments will strengthen capabilities in cell therapies and targeted radiation therapy and include global centers in Vienna and Shanghai that work with more than 500 clinical hospitals.[2] CEO Pascal Soriot said China is contributing to scientific innovation and global health.[1] The expansion will help the company grow and support jobs in the UK.[1]